ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ORAMED PHARMACEUTICALS INC. (ORMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 1-month period ending 2022-09-18, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2023-03-06
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2013 was 0.00%.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2012 was 0.00%.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2011 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|
| 2022-09-18 | 0.00% 10-Q · filed 2022-11-10 | ||
| 2022-05-02 | 0.00% 10-Q · filed 2022-11-10 | ||
| 2022-01-03 | 0.00% 10-Q · filed 2022-11-10 | ||
| 2021-08-04 | 0.00% 10-K · filed 2023-03-06 | ||
| 2021-02-17 | 0.00% 10-K · filed 2023-03-06 | ||
| 2021-02-03 | 0.00% 10-K · filed 2023-03-06 | ||
| 2020-01-08 | 0.00% 10-K · filed 2021-11-24 | ||
| 2014-08-31 | 0.00% 10-K · filed 2014-11-14 | ||
| 2013-08-31 | 0.00% 10-K · filed 2014-11-14 | ||
| 2012-08-31 | 0.00% 10-K · filed 2014-11-14 | ||
| 2011-08-31 | 0.00% 10-K · filed 2012-12-12 | ||
| 2011-07-31 | 0.00% 10-K · filed 2012-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |